Downloads: 2
Informative Article | Pharmacotherapeutics | Volume 11 Issue 6, June 2022 | Pages: 1369 - 1369 | India
Will Dostarlimab Become the New Rectal Cancer Drug of Choice?
Abstract: Information on a recent clinical trial in the United States on a drug that has been shown to be nearly 100% effective against rectal cancer in the sample population.
Keywords: Dostarlimab, Rectal cancer, new drug of choice
How to Cite?: Motupalli Sankeerth Kumar, Ponnaluri Lalitha, Seelam Victor John Wilson, "Will Dostarlimab Become the New Rectal Cancer Drug of Choice?", Volume 11 Issue 6, June 2022, International Journal of Science and Research (IJSR), Pages: 1369-1369, https://www.ijsr.net/getabstract.php?paperid=SR22617214828, DOI: https://dx.doi.org/10.21275/SR22617214828